Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Float Short %

12.77

Margin Of Safety %

-15

Put/Call OI Ratio

0.29

EPS Next Q Diff

-0.12

EPS Last/This Y

0.58

EPS This/Next Y

0.3

Price

8.56

Target Price

17.1

Analyst Recom

1.2

Performance Q

-17.61

Relative Volume

0.64

Beta

1.13

Ticker: BCRX




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-07-25BCRX8.560.340.0031169
2025-07-28BCRX8.270.340.0831323
2025-07-29BCRX8.090.340.0831568
2025-07-30BCRX8.230.330.0831663
2025-07-31BCRX8.140.330.0531774
2025-08-01BCRX7.950.330.7832188
2025-08-04BCRX8.730.380.0637849
2025-08-05BCRX8.360.370.0338078
2025-08-06BCRX8.60.360.0137871
2025-08-07BCRX8.350.360.0138043
2025-08-08BCRX8.310.350.0138589
2025-08-11BCRX8.190.350.4238525
2025-08-12BCRX8.350.350.8338977
2025-08-13BCRX8.530.350.0338936
2025-08-14BCRX8.450.350.1539362
2025-08-15BCRX8.360.340.5839419
2025-08-18BCRX8.390.290.0131627
2025-08-19BCRX8.270.290.0131939
2025-08-20BCRX8.390.290.3132106
2025-08-21BCRX8.380.290.0532300
2025-08-22BCRX8.560.290.0432427
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-07-25BCRX8.55145.0- 0.14
2025-07-28BCRX8.23143.1- 0.14
2025-07-29BCRX8.09143.1- 0.14
2025-07-30BCRX8.22143.1- 0.14
2025-07-31BCRX8.14143.1- 0.14
2025-08-01BCRX7.95143.1- 0.14
2025-08-04BCRX8.73143.1- 0.14
2025-08-05BCRX8.36143.1- 0.14
2025-08-06BCRX8.60154.4- 0.18
2025-08-07BCRX8.35154.4- 0.18
2025-08-08BCRX8.30147.9- 0.15
2025-08-11BCRX8.20147.9- 0.15
2025-08-12BCRX8.35147.9- 0.15
2025-08-13BCRX8.53147.9- 0.15
2025-08-14BCRX8.45147.9- 0.15
2025-08-15BCRX8.37147.9- 0.15
2025-08-18BCRX8.39147.9- 0.15
2025-08-19BCRX8.28147.9- 0.15
2025-08-20BCRX8.39147.9- 0.15
2025-08-21BCRX8.38147.9- 0.15
2025-08-22BCRX8.56147.9- 0.15
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-07-25BCRX0.008.2313.28
2025-07-28BCRX0.007.6813.28
2025-07-29BCRX0.007.6813.28
2025-07-30BCRX0.007.6813.28
2025-07-31BCRX0.007.6813.28
2025-08-01BCRX0.007.6813.28
2025-08-04BCRX0.007.3313.29
2025-08-05BCRX0.007.3313.29
2025-08-06BCRX0.007.3313.29
2025-08-07BCRX0.007.3313.29
2025-08-08BCRX0.007.3313.24
2025-08-11BCRX0.007.2913.24
2025-08-12BCRX0.007.2912.80
2025-08-13BCRX0.007.2912.80
2025-08-14BCRX0.007.2912.80
2025-08-15BCRX-0.907.2912.80
2025-08-18BCRX-0.903.8612.77
2025-08-19BCRX-0.963.8612.77
2025-08-20BCRX-0.963.8612.77
2025-08-21BCRX-0.963.8612.77
2025-08-22BCRX-0.963.8612.77
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS

0.15

Avg. EPS Est. Current Quarter

0.03

Avg. EPS Est. Next Quarter

0.03

Insider Transactions

-0.96

Institutional Transactions

3.86

Beta

1.13

Average Sales Estimate Current Quarter

162

Average Sales Estimate Next Quarter

155

Fair Value

7.28

Quality Score

72

Growth Score

58

Sentiment Score

47

Actual DrawDown %

57.2

Max Drawdown 5-Year %

-79.1

Target Price

17.1

P/E

Forward P/E

15.3

PEG

P/S

3.22

P/B

P/Free Cash Flow

115.93

EPS

-0.17

Average EPS Est. Cur. Y​

0.15

EPS Next Y. (Est.)

0.45

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-6.41

Relative Volume

0.64

Return on Equity vs Sector %

-16.2

Return on Equity vs Industry %

0.6

EPS 1 7Days Diff

EPS 1 30Days Diff

0.01

EBIT Estimation

BioCryst Pharmaceuticals, Inc.
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Employees: 580
BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and injectable protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in phase 1; Avoralstat, an ocular plasma kallikrein inhibitor for diabetic macular edema that is in preclinical phase; and BCX10013, an oral Factor D inhibitor for complement-mediated diseases, as well as developing Oral C5 Inhibitor and Oral C2 Inhibitor. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Shionogi & Co., Ltd., Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
stock quote shares BCRX – BioCryst Pharmaceuticals, Inc. Stock Price stock today
news today BCRX – BioCryst Pharmaceuticals, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch BCRX – BioCryst Pharmaceuticals, Inc. yahoo finance google finance
stock history BCRX – BioCryst Pharmaceuticals, Inc. invest stock market
stock prices BCRX premarket after hours
ticker BCRX fair value insiders trading